Item 1.01 Entry Into a Material Definitive Agreement.
Business Combination Agreement
This section describes the material provisions of the Business Combination
Agreement (as defined below), but does not purport to describe all of the terms
thereof. The following summary is qualified in its entirety by reference to the
complete text of the Business Combination Agreement, a copy of which is attached
hereto as Exhibit 2.1. Shareholders of
General Terms and Effects; Merger Consideration
On
Pursuant to the Business Combination Agreement, subject to the terms and
conditions set forth therein, at the Effective Time (as defined below), (a) a
to-be-incorporated wholly-owned subsidiary of Psyence Biomed domiciled in the
As consideration for the Merger, as of the effective time of the Merger (the
"Effective Time") (i) each Class B ordinary share, par value
Before or upon the Closing, Psyence Biomed intends to transfer the shares of
In connection with the transactions contemplated by the Business Combination
Agreement (the "Transaction"), Newcourt and Psyence Biomed also intend to enter
into Subscription Agreements with certain investors, prior to the consummation
of the Transaction (the "Closing"), to provide financing to Newcourt, Psyence
Biomed or the Combined Company (the "
Immediately prior to the consummation of the
Representations and Warranties
The Business Combination Agreement contains a number of representations and warranties made by the parties as of the date of the Business Combination Agreement or other specified dates. Certain of the representations and warranties are qualified by materiality or Material Adverse Effect (as hereinafter defined), as well as information provided in the disclosure schedules to the Business Combination Agreement. As used in the Business Combination Agreement, "Material Adverse Effect" means, with respect to any specified person or entity, any event, circumstance or state of facts that has had, or would reasonably be expected to have, individually or in the aggregate, a material and adverse effect upon (i) the business, results of operations or financial condition of such person or entity and, taken as a whole, or (ii) the ability of such person or entity to perform its respective obligations and to consummate the transactions contemplated by the Business Combination Agreement and the Ancillary Agreements, in each case, subject to certain customary exceptions.
No Survival
The representations and warranties of the parties contained in the Business Combination Agreement terminate as of, and do not survive, the Closing. The covenants and agreements of the parties contained in the Business Combination Agreement do not survive the Closing, except those covenants and agreements to be performed after the Closing, and then only with respect to any breaches occurring on or after the Closing.
Covenants of the Parties
The Business Combination Agreement also contains certain customary covenants by
each of the parties during the period between the signing of the Business
Combination Agreement and the earlier of the Closing or the termination of the
Business Combination Agreement in accordance with its terms (the "Interim
Period"), including those relating to: (i) commercially reasonable efforts to
effect the Closing; (ii) the movement of the funds from the Trust Account at
Closing; (iii) maintenance of listing on the
The parties made customary covenants regarding the registration statement on
Form F-4 to be filed by Newcourt (the "Registration Statement") with the
The parties agreed that the post-Closing board of directors will consist of five directors designated prior to the Closing, including one director designated by the Sponsor, one independent director (under Nasdaq requirements) mutually designated by Newcourt and Psyence, and the remaining directors designated by Psyence. The parties further agreed each director and officer of Newcourt will resign at the Closing.
Furthermore, at the Closing, the Parties intend to amend and restate the Registration and Shareholder Rights Agreement (the "A&R Registration Rights Agreement") to apply to securities of Psyence Biomed, and (ii) at or prior to the Closing, Psyence Biomed will amend and restate its existing Memorandum and Articles to effect the Stock Split.
Conditions to Closing
The Business Combination Agreement contains customary conditions to Closing,
including the following mutual conditions of the parties (unless waived): (i) no
law or order preventing the Transaction; (ii) approval of the shareholders of
Newcourt; (iii) if required by the Canadian Stock Exchange Rules, the approval
by shareholders of Psyence; (iv) completion of any required stock exchange or
regulatory review and receipt of any mutually agreed required regulatory
approvals; (v) the Registration Statement having been declared effective by the
In addition, unless waived, the obligations of Psyence and Psyence Biomed to
consummate the Transaction are subject to the satisfaction of the following
additional Closing conditions, in addition to the delivery by Newcourt of
customary certificates and other Closing deliverables: (i) the representations
and warranties of Newcourt being true and correct as of the date of the Closing,
except to the extent made as of a particular date (subject to certain
materiality qualifiers); (ii) Newcourt and the Sponsor having performed in all
material respects its obligations and complied in all material respects with its
covenants and agreements under the Business Combination Agreement required to be
performed or complied with by it on or prior to the date of the Closing; (iii)
the absence of any Material Adverse Effect with respect to Newcourt since the
date of the Business Combination Agreement; (iv) delivery of a duly executed
officer's certificate certifying certain conditions; (v) Newcourt having, at the
Closing, at least
Unless waived, the obligations of Newcourt to consummate the Transaction are subject to the satisfaction of the following additional Closing conditions, in addition to the delivery by Psyence of customary certificates and other Closing deliverables: (i) the representations and warranties of Psyence and Psyence Biomed being true and correct as of the date of the Closing, except to the extent made as of a particular date (subject to certain materiality qualifiers); (ii) Psyence Biomed having performed in all material respects its obligations and complied in all material respects with its covenants and agreements under the Business Combination Agreement required to be performed or complied with or by it on or prior to the date of the Closing; (iii) the absence of any Material Adverse Effect with respect to Psyence or Psyence Biomed since the date of the Business Combination Agreement; (iv) delivery of a duly executed officer's certificate certifying certain conditions; (v) Psyence and Psyence Biomed shall have executed and delivered a copy of each Ancillary Agreement to which they are a party; (vi) delivery by Psyence Biomed to Newcourt of certain financial statements; and (vii) a fairness opinion shall have been received by Newcourt.
Termination
The Business Combination Agreement may be terminated under certain customary and
limited circumstances at any time prior to the Closing, including: (i) by mutual
written consent of Newcourt and Psyence; (ii) by either Newcourt or Psyence if
any applicable law is in effect which makes the consummation of the Transactions
illegal or any final, non-appealable order if in effective permanently
preventing the consummation of the Transactions, unless such order or other
action was caused by the breach of such party; (iii) by either Newcourt or
Psyence if the consummation of the transactions contemplated by the Business
Combination Agreement shall not have occurred on or before
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description 2.1* Business Combination Agreement, dated as ofJanuary 9, 2023 , by and amongNewcourt Acquisition Corp ,Newcourt SPAC Sponsor LLC , Psyence Group Inc. andPsyence Biomed Corp. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
* The exhibits and schedules to this Exhibit have been omitted in accordance
with Item 601(b)(2) of Regulation S-K. The Registrant agrees to furnish
supplementally to the
© Edgar Online, source